touchLearning Activities
Education, Conference Coverage and Articles
How advances in molecular understanding are shaping Parkinson's disease classification, patient stratification, and the future of personalized care Parkinson’s disease has historically been diagnosed and classified primarily according to clinical features. However, advances in genetics, molecular biomarkers, and our ...
Prof. Kenneth Gorson discusses the unmet need in Guillain–Barré syndrome, the phase 3 GBS-02 trial data evaluating tanruprubart, and how complement inhibition could improve recovery while reducing the long-term healthcare burden of this disabling disease. [touchplayvideo video_id="nt33qaui86"] &...
Highlights from the European Academy of Neurology (EAN) 2026 Congress included new phase 3 data in ocular myasthenia gravis, emerging migraine treatments, longer-term results in multiple sclerosis, and advances in deep brain stimulation for Parkinson’s disease. The 12th Congress of the ...
Leading Alzheimer's disease experts share the therapeutic and research developments they believe had the greatest potential to transform diagnosis, treatment and prevention at the Alzheimer's Association International Conference (AAIC) 2026. The Alzheimer's Association International Conference (AAIC) 2026 showcased advances across the Alzheimer's ...
Could NLRP3 be the missing link between amyloid pathology and tau-mediated neurodegeneration? Dr Gennaro Pagano explains how insights from the GRADUATE trial is informing the next generation of Alzheimer's disease therapies and advancing our understanding of neuroinflammation. https://touchmedicalmedia-1.wistia.
Prof. Arcadi Navarro discusses BBRC's largest-ever presence at AAIC, the growing role of biomarkers and personalized risk prediction, and why prevention is becoming the future of Alzheimer's disease research. Introduction We spoke with Prof. Arcadi Navarro, Professor of Genetics and ...
Dr Reisa Sperling discusses the rationale for targeting preclinical Alzheimer's disease, the latest long-term data from the Brainshuttle AD programme evaluating trontinemab, and how the PrevenTRON study could help shift Alzheimer's disease treatment towards prevention. We spoke with Dr Reisa ...
Dr Klaus Dugi discusses the first-in-human data for VNA-318, the rationale for targeting cellular energy metabolism in Alzheimer's disease, and how improving mitochondrial function could offer both symptomatic and disease-modifying benefits. We spoke with Klaus Dugi, Chief Executive Officer of ...
Prof. John-Paul Taylor discusses the phase 2b RewinD-LB findings, lessons learned from the neflamapimod programme, and the next steps towards precision medicine in dementia with Lewy bodies We spoke with Prof. John-Paul Taylor, Newcastle University, Newcastle upon Tyne, UK, at ...
Prof. George Grossberg discusses the unmet need in agitation associated with Alzheimer's disease, the rationale behind the phase 3 ADAGIO studies, and the evolving role of biomarkers and caregivers in improving patient care. We spoke with Prof. George Grossberg, Saint Louis ...
Large real-world study highlights important ethnoracial differences in amyloid positivity and their implications for diagnosis, treatment and clinical trial access As amyloid biomarkers become central to Alzheimer's disease diagnosis and treatment, a new analysis from the New IDEAS (Imaging Dementia—...
Meet the future leaders transforming neurology The touchNEUROLOGY Future Leaders 2026 programme recognizes outstanding early- and mid-career clinicians, researchers and scientists who are shaping the future of neurology. Nominated by peers across the global neurology community, these innovators are leading advances ...
We are delighted to announce Dr Ahmed Abdelhak as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in blood biomarkers in multiple sclerosis. We spoke with Dr Ahmed Abdelhak (Department of ...
We are delighted to announce Dr Roopa Rajan as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of Parkinson's disease and movement disorders. We spoke with Dr Roopa Rajan (All India Institute of ...
We are delighted to announce Dr ​​Robin Zhou as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of Alzheimer's disease. Dr Robin Zhou (Karolinska Institutet, Stockholm, Sweden) is an MD and PhD student ...
We are delighted to announce Dr Sarah Haigh as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in sensory symptoms in neurological disorders. We spoke with Dr Sarah Haigh (Department of ...
We are delighted to announce Dr Carolina Dal Bo as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of research in rare inflammatory disorders of the central nervous system. From falling in love ...
touchNEUROLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
